Announcements Trials
Browse Landscape

Status

No longer available 3Approved for marketing 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 486Observational 29Expanded_access 4

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1Thoracic 1

Conditions

Melanoma 2Squamous Non-Small Cell Lung Cancer 1Neoplasms 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Nivolumab × Clear all
NCT06590480 2025-12-18

RPL-EAP-001

Replimune, Inc.

No longer available
Dermatologic

Melanoma

NCT03126643 2021-11-29

Expanded Access to Nivolumab (Opdivo)

Bristol-Myers Squibb

Approved for marketing
Tumor-Agnostic

Neoplasms

NCT02475382 2020-11-27

CheckMate 169

Bristol-Myers Squibb

No longer available
Thoracic

Squamous Non-Small Cell Lung Cancer

NCT02186249 2017-02-08

CheckMate218

Bristol-Myers Squibb

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡